Shen Hao, Ding Jiayu, Ji Jiaying, Hu Lingrong, Min Wenjian, Hou Yi, Wang Dawei, Chen Yuanyuan, Wang Liping, Zhu Yasheng, Wang Xiao, Yang Peng
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
J Med Chem. 2025 Jan 23;68(2):1844-1862. doi: 10.1021/acs.jmedchem.4c02574. Epub 2025 Jan 10.
MTDH-SND1 protein-protein interaction (PPI) plays an important role in the initiation and development of tumors, and it is a target for the treatment of breast cancer. In this study, we identified and synthesized a series of novel small-molecule inhibitors of MTDH-SND1 PPI. The representative compound showed potent activity against MTDH-SND1 PPI with an IC of 487 ± 99 nM and tight binding to the SND1-purified protein with a value of 279 ± 17 nM. Compound significantly degraded SND1 and downregulated downstream at the protein level. Further biological evaluations suggested that compound exhibited potent activity against the proliferation of breast cancer MCF-7 cells with an IC value of 626 ± 27 nM, significantly inhibited invasion and migration, and induced cell apoptosis. In addition, compound exhibited promising tumor growth inhibition in the xenograft model. Our study provides a potential candidate targeting MTDH-SND1 PPI for the treatment of breast cancer.
MTDH-SND1蛋白-蛋白相互作用(PPI)在肿瘤的发生和发展中起重要作用,是乳腺癌治疗的一个靶点。在本研究中,我们鉴定并合成了一系列新型的MTDH-SND1 PPI小分子抑制剂。代表性化合物对MTDH-SND1 PPI显示出强效活性,IC50为487±99 nM,与纯化的SND1蛋白紧密结合,KD值为279±17 nM。化合物显著降解SND1并在蛋白水平下调其下游分子。进一步的生物学评价表明,化合物对乳腺癌MCF-7细胞的增殖显示出强效活性,IC50值为626±27 nM,显著抑制侵袭和迁移,并诱导细胞凋亡。此外,化合物在异种移植模型中表现出有前景的肿瘤生长抑制作用。我们的研究为治疗乳腺癌提供了一个靶向MTDH-SND1 PPI的潜在候选物。